On May 16, 2018 Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, reported that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held June 1 – 5, 2018 in Chicago, Illinois (Press release, Odonate Therapeutics, MAY 16, 2018, View Source [SID1234526730]). Abstracts for these presentations were made publicly available today and can be found on the ASCO (Free ASCO Whitepaper) website at View Source and by clicking the titles below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Abstract 1042 (Poster Board #123): Activity of Tesetaxel, an Oral Taxane, Given as a Single-agent in Patients (Pts) with HER2-, Hormone Receptor + (HR+) Locally Advanced or Metastatic Breast Cancer (MBC) in a Phase 2 Study
Presenter:Andrew Seidman, M.D.
Poster Session: Breast Cancer – Metastatic
Date/Time:Saturday, June 2, 2018 / 8:00AM – 11:30AM (CT)
Location: Hall A
Abstract TPS1106 (Poster Board #184a): CONTESSA: A Multinational, Multicenter, Randomized, Phase 3 Registration Study of Tesetaxel in Patients (Pts) with HER2-, Hormone Receptor + (HR+) Locally Advanced or Metastatic Breast Cancer (MBC)
Presenter:Joyce O’Shaughnessy, M.D.
Poster Session: Breast Cancer – Metastatic
Date/Time:Saturday, June 2, 2018 / 8:00AM – 11:30AM (CT)
Location: Hall A
About Tesetaxel
Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; no history of hypersensitivity (allergic) reactions; and robust activity against chemotherapy-resistant tumors. More than 500 patients have been treated with tesetaxel across 22 clinical studies. In patients with locally advanced or metastatic breast cancer (MBC), tesetaxel was shown to have robust single-agent antitumor activity in two, multicenter, Phase 2 studies.
About CONTESSA
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with locally advanced or metastatic breast cancer (MBC). CONTESSA will compare tesetaxel dosed orally at 27 mg/m2 on the first day of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day dosed orally on days 1-14 of a 21-day cycle) to the approved dose of capecitabine alone (2,500 mg/m2/day dosed orally on days 1-14 of a 21-day cycle) in approximately 600 patients randomized 1:1 with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC. Where indicated, patients must have received endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. The primary endpoint is progression-free survival (PFS) assessed by an Independent Radiologic Review Committee (IRC). CONTESSA’s secondary efficacy endpoints are overall survival, objective response rate (ORR) assessed by IRC, disease control rate assessed by IRC and patient-reported outcomes. To learn more, please visit www.contessastudy.com.